Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Bokf Na

BOKF NA increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 83.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,203 shares of the biopharmaceutical company's stock after purchasing an additional 1,458 shares during the quarter. BOKF NA's holdings in Regeneron Pharmaceuticals were worth $2,232,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $28,000. Rakuten Securities Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares during the last quarter. Avalon Trust Co acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $36,000. Crowley Wealth Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $36,000. Finally, Private Wealth Management Group LLC raised its holdings in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after acquiring an additional 39 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

REGN has been the subject of a number of analyst reports. UBS Group cut their price target on Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. Citigroup dropped their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. The Goldman Sachs Group dropped their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Guggenheim dropped their target price on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Finally, Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $892.60.

Regeneron Pharmaceuticals Stock Up 9.1%

Shares of NASDAQ REGN traded up $48.25 on Monday, hitting $576.03. The company had a trading volume of 1,372,863 shares, compared to its average volume of 772,646. Regeneron Pharmaceuticals, Inc. has a 12-month low of $517.05 and a 12-month high of $1,211.20. The business has a 50 day moving average of $613.08 and a two-hundred day moving average of $693.43. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $62.97 billion, a P/E ratio of 15.08, a PEG ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same period in the previous year, the company earned $9.55 EPS. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% on a year-over-year basis. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.